Biological Evaluation Report (BER) Expectations

Biological Evaluation Report (BER) Expectations

Introduction

The Biological Evaluation Report (BER) is one of the most critical documents in a medical device regulatory submission.

While the Biological Evaluation Plan (BEP) explains what will be done, the BER demonstrates what was done and why the device is biologically safe.

Regulatory authorities such as the US FDA and EU Notified Bodies carefully review the BER to confirm that biocompatibility risks have been properly assessed and controlled.

With ISO 10993-1:2025, expectations for the BER have become clearer and more demanding.

Regulators now expect strong scientific justification, clear linkage to risk management and comprehensive evaluation of chemical and biological data.

In this blog, Accuprec Research Labs Pvt. Ltd. explains BER expectations and how to prepare a regulatory-ready report.

What Is a Biological Evaluation Report (BER)?

A Biological Evaluation Report is a documented assessment that summarizes and evaluates all biocompatibility-related information for a medical device.

It concludes whether the device is biologically safe for its intended use.

The BER is a decision-making document that integrates:

• Device and material information
• Risk management data
• Chemical characterization results
• Biological test results
• Toxicological risk assessments
• Clinical and literature data

Purpose of the BER in Regulatory Submissions

Regulatory authorities rely on the BER to:

• Confirm patient safety
• Evaluate the adequacy of the biological evaluation strategy
• Verify compliance with ISO 10993 standards
• Ensure risks are identified, controlled and acceptable

A weak or incomplete BER often results in regulatory questions or rejection.

Role of BER in ISO 10993-1:2025

ISO 10993-1:2025 places strong emphasis on clear documentation and scientific justification.

The BER must:

• Be aligned with the BEP
• Be integrated with ISO 14971 risk management
• Reflect a risk-based, science-driven approach

The BER is no longer a summary of test reports; it is a comprehensive safety assessment.

Key Components of a Strong BER

1. Device Description and Intended Use

The BER should start with a concise but clear description of:

• Device design and function
• Intended use and indications
• Patient population
• Nature and duration of body contact

This context is essential for evaluating biological risk.

2. Summary of the Biological Evaluation Plan

The BER should reference the BEP and confirm:

• The planned evaluation strategy
• Any deviations from the plan
• Justification for changes

Consistency between BEP and BER is critical.

3. Risk Management Integration

ISO 10993-1:2025 requires strong alignment with ISO 14971.

The BER should:

• Reference biological hazards identified in the risk analysis
• Describe risk control measures
• Evaluate residual biological risks

This integration demonstrates a controlled safety approach.

4. Material and Manufacturing Assessment

The BER must include an evaluation of:

• Raw materials and additives
• Manufacturing processes
• Sterilization methods
• Potential process-related contaminants

This helps identify sources of biological risk.

5. Chemical Characterization and Exposure Assessment

Chemical characterization plays a central role in modern BERs.

The report should include:

• Summary of extractables and leachables data
• Identification of chemical constituents
• Estimation of patient exposure

This information supports toxicological risk assessment.

6. Toxicological Risk Assessment

Under ISO 10993-17, toxicological risk assessment is used to:

• Evaluate identified chemicals
• Compare exposure levels to safe limits
• Determine whether risks are acceptable

The BER should clearly summarize conclusions from toxicological assessments.

7. Evaluation of Biological Test Data

When biological testing is conducted, the BER should:

• Summarize test methods and standards used
• Present results clearly
• Evaluate relevance to intended use

Negative or borderline results must be scientifically addressed.

8. Use of Existing and Clinical Data

ISO 10993-1:2025 encourages use of:

• Previous biocompatibility studies
• Clinical data
• Post-market surveillance
• Published literature

The BER should critically assess relevance and adequacy of such data.

Common BER Deficiencies Noted by Regulators

Regulatory reviewers often raise concerns when BERs:

• Lack scientific justification
• Are not aligned with risk management
• Ignore chemical characterization data
• Simply list test results without evaluation
• Do not clearly conclude biological safety

Avoiding these issues improves regulatory outcomes.

Regulatory Expectations for BER Review

Regulators expect the BER to be:

• Clear and logically structured
• Device-specific and risk-based
• Supported by scientific rationale
• Consistent with BEP and other submission documents

A well-prepared BER increases reviewer confidence.

Benefits of a High-Quality BER

A strong BER offers several benefits:

• Faster regulatory reviews
• Fewer deficiency letters
• Reduced need for additional testing
• Improved patient safety assurance

It also supports lifecycle management and post-market activities.

How Accuprec Research Labs Supports BER Preparation

Accuprec Research Labs Pvt. Ltd. provides expert support for BER preparation, including:

• ISO 10993-1:2025–compliant BER drafting
• Integration with risk management files
• Chemical characterization and toxicology support
• Regulatory-ready documentation for FDA and EU MDR

Our approach ensures clarity, compliance and confidence.

Conclusion

The Biological Evaluation Report is a cornerstone of medical device biocompatibility documentation.

Under ISO 10993-1:2025, the BER must demonstrate a risk-based, science-driven evaluation supported by strong scientific evidence.

Manufacturers who invest in high-quality BERs are better positioned for smooth regulatory reviews and successful global approvals.